Power Law company profile

TG Therapeutics

Biotech & Life Sciences · New York City, United States · Founded 2011 · IPO 2003 Unicorn

TG Therapeutics - A Biopharmaceutical Company

Valuation

$5.50B

Market cap · May/2026

Revenue

$616M

Latest reported FY

EBITDA

$254M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where TG Therapeutics has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States99.5%

🇧🇩 Bangladesh0.4%

🇮🇱 Israel0.3%

3 countries shown

Web traffic by country

40K monthly visits
across markets

🇺🇸 United States20%

🇨🇦 Canada4%

🇬🇧 United Kingdom3.5%

🇯🇵 Japan3.3%

🇮🇳 India3%

Top 5 markets shown

Patent intelligence

$675k patent portfolio · 7 active families

Estimated portfolio value

$675k

0.01% of market cap · 485.8× smaller than top peer Genmab ($328M)

7 active patent families

Where TG Therapeutics innovates Antiendomysial antibodiesMolecular biologyAnti antibodyImmunologyKinase

Where TG Therapeutics concentrates vs peers

Each axis is a top-10 topic across TG Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about TG Therapeutics

An AI-synthesized read of the highest-engagement posts about TG Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TG Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles